CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
Abstract The chimera antigen receptor (CAR) T cell therapy is a novel and potential targeted therapy and has achieved satisfactory efficacy in patients with relapsed or refractory multiple myeloma (MM) in recent years. However, cytokine release syndrome (CRS) and clinical efficacy have become the ma...
Main Authors: | Mengying Ke, Liqing Kang, Ling Wang, Shu Yang, Yajun Wang, Haiyan Liu, Chunyan Gu, Hongming Huang, Ye Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-06-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13045-021-01101-6 |
Similar Items
-
CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
by: Massimo Martino, et al.
Published: (2021-05-01) -
Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma
by: Marcin Jasiński, et al.
Published: (2021-02-01) -
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
by: Gils Roex, et al.
Published: (2020-12-01) -
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
by: Luis Gerardo Rodríguez-Lobato, et al.
Published: (2020-07-01) -
Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
by: Estefanía García-Guerrero, et al.
Published: (2020-06-01)